Varifarma signed an exclusive distribution and licensing agreement for QARZIBA® in Argentina with EUSA Pharma (UK) Ltd.
QARZIBA® is a cancer medicine used to treat neuroblastoma, a cancer of nerve cells, in patients over 1 year of age. It is used in 2 groups of patients who have high-risk neuroblastoma (which has a high chance of coming back): patients who have had some improvement with previous treatments, which included blood stem-cell transplantation and patients whose neuroblastoma has not improved with other cancer treatments or has come back. Because the number of patients with neuroblastoma is low, the disease is considered ‘rare’, and QARZIBA® was designated an ‘orphan medicine’ on November 2012.
Lic. Marcelo Conti, Laboratorio Varifarma Director, commented: “A few years ago, at Varifarma we set out to bridge the gap between Argentine rare disease patients with unsatisfied needs and their access to innovative and effective therapies; QARZIBA® is one more step in that direction. We are very proud to receive this license and the confidence of EUSA Pharma that our team will work deeply committed to fulfill their expectations”.